Aptose Biosciences Inc. (APS) - Presentations

TUSCANY Study Demonstrates Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Ineligible for Induction Chemotherapy

Sat, 06 Dec 2025 00:00:00 -0500

ESH 2025 Poster - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy

Thu, 16 Oct 2025 00:00:00 -0400

TUS Triplet TUSCANY Trial Update - August 2025

Thu, 21 Aug 2025 00:00:00 -0400

EHA 2025 - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy

Thu, 12 Jun 2025 00:00:00 -0400

Aptose Corporate Presentation - Bloom Burton Conference

Mon, 05 May 2025 00:00:00 -0400

Aptose Corporate Presentation March 2025

Tue, 11 Mar 2025 00:00:00 -0400

Aptose Corporate Presentation January 2025

Mon, 13 Jan 2025 00:00:00 -0500

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Mon, 09 Dec 2024 00:00:00 -0500

Aptose Corporate Presentation November 2024

Thu, 07 Nov 2024 00:00:00 -0500

Aptose Corporate Presentation July 2024

Fri, 26 Jul 2024 00:00:00 -0400

2024 EHA Poster – Tuspetinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax

Fri, 14 Jun 2024 00:00:00 -0400

2024 EHA Poster – Safety and Efficacy of Tuspetinib as Monotherapy and Combined with Venetoclax in a Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Fri, 14 Jun 2024 00:00:00 -0400

Aptose 1Q Earnings Presentation

Tue, 14 May 2024 00:00:00 -0400

Aptose Corporate Presentation May 2024

Fri, 03 May 2024 00:00:00 -0400

Aptose Corporate Presentation December 2023

Tue, 26 Dec 2023 00:00:00 -0500

Investor Fact Sheet

Thu, 14 Dec 2023 00:00:00 -0500

Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Sat, 09 Dec 2023 00:00:00 -0500

Tuspetinib Clinical Update and KOL Data Review

Mon, 30 Oct 2023 00:00:00 -0400

2023 ESH Poster – Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax

Sun, 29 Oct 2023 00:00:00 -0400

2023 ESH Poster – Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy as Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Sun, 29 Oct 2023 00:00:00 -0400

Aptose Corporate Presentation September 2023

Mon, 11 Sep 2023 00:00:00 -0400

Aptose Interim Clinical Update

Sat, 10 Jun 2023 00:00:00 -0400

In conjunction with EHA 2023

Aptose Corporate Presentation April 2023

Thu, 13 Apr 2023 00:00:00 -0400

Aptose Corporate Presentation January 2023

Fri, 06 Jan 2023 00:00:00 -0500

Aptose ASH Clinical Update and Data Review

Sun, 11 Dec 2022 00:00:00 -0500

2022 ASH Poster - A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Sun, 11 Dec 2022 00:00:00 -0500

2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies

Sun, 11 Dec 2022 00:00:00 -0500

2022 ASH Poster - A Phase 1 a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes

Sun, 11 Dec 2022 00:00:00 -0500

Aptose Corporate Presentation September 2022

Mon, 12 Sep 2022 00:00:00 -0400

Aptose Corporate Presentation August 2022

Fri, 19 Aug 2022 00:00:00 -0400

Aptose Corporate Presentation July 2022

Tue, 19 Jul 2022 00:00:00 -0400

Aptose Corporate Presentation June 2022

Mon, 27 Jun 2022 00:00:00 -0400

2022 EHA Poster - Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models

Fri, 10 Jun 2022 00:00:00 -0400

Aptose KOL Event and Clinical Update

Thu, 02 Jun 2022 00:00:00 -0400

Aptose Corporate Presentation March 2022

Tue, 15 Mar 2022 00:00:00 -0400

Aptose Corporate Update at ASH 2021

Mon, 13 Dec 2021 00:00:00 -0500

2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS

Mon, 13 Dec 2021 00:00:00 -0500

2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML

Mon, 13 Dec 2021 00:00:00 -0500

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML

Sat, 11 Dec 2021 00:00:00 -0500

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies

Sat, 11 Dec 2021 00:00:00 -0500

Aptose Corporate Update at EHA 2021

Fri, 11 Jun 2021 00:00:00 -0400

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies

Fri, 11 Jun 2021 00:00:00 -0400

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS

Fri, 11 Jun 2021 00:00:00 -0400

Aptose Corporate Update at ASH 2020

Sun, 06 Dec 2020 00:00:00 -0500

2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL

Sun, 06 Dec 2020 00:00:00 -0500

2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS

Sat, 05 Dec 2020 00:00:00 -0500

2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas

Mon, 22 Jun 2020 00:00:00 -0400

2020 EHA Poster - Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with R/R CLL/SLL or NHL

Fri, 12 Jun 2020 00:00:00 -0400

2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL

Mon, 27 Apr 2020 00:00:00 -0400

Key Opinion Leader Symposium: CG-806 for AML

Wed, 05 Feb 2020 00:00:00 -0500

2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mon, 09 Dec 2019 00:00:00 -0500

2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Sun, 08 Dec 2019 00:00:00 -0500

Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253

Sat, 07 Dec 2019 00:00:00 -0500

2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML

Thu, 24 Oct 2019 00:00:00 -0400

2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR

Fri, 14 Jun 2019 00:00:00 -0400

24th Congress of The European Hematology Association 2019 - CG-806, Preclinica…

Thu, 16 May 2019 00:00:00 -0400

2019 AACR Poster - Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in Raji B cells

Mon, 01 Apr 2019 00:00:00 -0400

2019 AACR Poster - CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

Mon, 01 Apr 2019 00:00:00 -0400

Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers

Wed, 12 Dec 2018 00:00:00 -0500

2018 ASH Poster – CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Sun, 02 Dec 2018 00:00:00 -0500

2018 ASH Poster – Concomitant Targeting of FLT3 and BTK with CG-806 Overcomes FLT3-Inhibitor Resistance Through Inhibition of Autophagy

Sun, 02 Dec 2018 00:00:00 -0500

2018 EHA Poster - CG-806, a Non Covalent Pan-FLT3/Pan-BTK Inhibitor, Exhibits Unique Binding to Wild Type and C481S Mutant BTK and Greater Potency Than Ibrutinib Against Malignant B Cells

Fri, 15 Jun 2018 00:00:00 -0400

2018 AACR Poster - APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency

Tue, 17 Apr 2018 00:00:00 -0400

2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

Sun, 15 Apr 2018 00:00:00 -0400

2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples

Sun, 15 Apr 2018 00:00:00 -0400

2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples

Mon, 11 Dec 2017 00:00:00 -0500

2017 ASH Poster - CG’806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutational Status

Mon, 11 Dec 2017 00:00:00 -0500

2017 ASH Poster - The Pan-FLT3/BTK Multi-Kinase Inhibitor CG’806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1

Sun, 10 Dec 2017 00:00:00 -0500

2017 AACR Hematologic Malignancies Conference - CG’806, a First‐in‐Class FLT3/BTK Inhibitor, Exerts Superior Potency Against AML Cells Harboring FLT3‐ITD, TKD, and Gatekeeper Mutant or Wild‐Type FLT3

Sun, 07 May 2017 00:00:00 -0400

2017 AACR Hematologic Malignancies Conference - CG’806, a First-in-Class FLT3/BTK Inhibitor, Exhibits Potent Activity Against AML

Sun, 07 May 2017 00:00:00 -0400

2016 ASH Poster - Inhibition of c-Myc by APTO-253 as an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Sat, 03 Dec 2016 00:00:00 -0500